 |
인쇄하기
취소
|
Jeil, Takeda Korea to cooperate over new treatment of type 2 diabetes
Jeil Pharm and Takeda Korea announced Wednesday that they have concluded an agreement to co-promote Nesina (alogliptin), Takeda’s new treatment for type 2 diabetes in adults as adjuncts to diet and exercise.
Nesina is a dipeptidyl peptidase-4 (DPP-4) inhibitor that is designed to slow the inactivation of incretin hormones GLP-1 (glucagon-like peptide-1) and GIP (glucose-dependent insulinotro...
Nesina is a dipeptidyl peptidase-4 (DPP-4) inhibitor that is designed to slow the inactivation of incretin hormones GLP-1 (glucagon-like peptide-1) and GIP (glucose-dependent insulinotro...
Fees
- Email service daily and homepage access.
- $300 per month.
- 5 Email holders per each company.
- Anual contract base.
Copyright Yakup.com All rights reserved.
약업닷컴의 모든 컨텐츠는 저작권법의 보호를 받습니다. 무단 전재⋅복사⋅배포 등을 금합니다.
약업닷컴의 모든 컨텐츠는 저작권법의 보호를 받습니다. 무단 전재⋅복사⋅배포 등을 금합니다.